Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
Background: Although with the introduction of novel agents, clinical outcomes have significantly improved in patients of multiple myeloma (MM); however, nearly all relapse, requiring subsequent treatment. Patients who have been heavily treated for relapsed/refractory MM (RRMM) have limited options a...
Saved in:
| Main Authors: | A P Dubey, Sameer Khatri, Sachin Maggo, Nilabh K Singh, Durgesh Sharma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=6;spage=846;epage=849;aulast=Dubey |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
by: Barry Paul, et al.
Published: (2025-06-01) -
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
by: Chia Jie Tan, et al.
Published: (2025-03-01) -
Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01) -
Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01) -
Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma
by: Lin Wang, et al.
Published: (2025-12-01)